Tall oil, compd. with diethanolamine

Endpoint summary

Description of key information

ACUTE TOXICITY: ORAL
- LD50 >2000 mg/kg bodyweight in female Wistar strain rats

ACUTE TOXICITY: DERMAL
- LD50 >2000 mg/kg bw in male and female Wistar rats

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The key study was conducted under GLP conditions in accordance with the standardised guidelines OECD 420 and EU Method B.1 bis. It was assigned a reliability score of 1 in accordance with the criteria detailed by Klimisch (1997).

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

3 October 2012 to 17 October 2012

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Strain: RccHan:WIST
- Age at study initiation: 8 to 12 weeks
- Weight at study initiation: The animals weighed at least 200 g. The bodyweight variation did not exceed ± 20 % of the mean weight for each sex.
- Fasting period before study: No.
- Housing: The animals were housed in suspended solid-floor polypropylene cages furnished with woodflakes. Animals were housed individually during the 24 hour exposure period and in groups of 5, by sex, for the remainder of the study.
- Diet (e.g. ad libitum): ad libitum.
- Water (e.g. ad libitum): ad libitum access to mains drinking water.
- Acclimation period: At least 5 days.

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25 °C
- Humidity (%): 30 to 70 %
- Air changes (per hr): At least 15 changes per hour.
- Photoperiod (hrs dark / hrs light): The lighting was controlled by a time switch to give twelve hours continuous light (0600 to 1800) and twelve hours darkness.

IN-LIFE DATES: From: 3 October 2012 To: 17 October 2012

Type of coverage:

semiocclusive

Vehicle:

arachis oil

Details on dermal exposure:

TEST SITE
- Preparation: On the day before treatment, the back and flanks of each animal were clipped free of hair.
- % coverage: Approximately 10 % of the total body surface area.
- Type of wrap if used: A piece of surgical gauze was placed over the treatment area and semi-occluded with a piece of self-adhesive bandage.

REMOVAL OF TEST SUBSTANCE
- Washing (if done): The treated skin and surrounding hair were wiped with cotton wool moistened with arachis oil BP to remove any residual test material.
- Time after start of exposure: 24 hours.

TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bodyweight.

VEHICLE
- Amount(s) applied: The appropriate amount of the test material was moistened with arachis oil BP and applied as evenly as possible.

Duration of exposure:

24 hours

Doses:

2000 mg/kg

No. of animals per sex per dose:

5 animals per sex per dose

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for deaths or overt signs of toxicity 0.5, 1, 2 and 4 hours after dosing and subsequently once daily for 14 days.
After the removal of the dressings and subsequently once daily for 14 days, the test sites were examined for any evidence of primary irritation and scored according to the criteria of Draize (shown below).
Individual bodyweights were recorded prior to application of the test material on day 0 and on days 7 and 14.
- Necropsy of survivors performed: Yes; all animals were subjected to gross necropsy. Animals were killed by cervical dislocation. An external examination was performed and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded.


Draize Scale for Primary Irritation:

Erythema and eschar formation:
No erythema 0
Very slight erythema (barely perceptible) 1
Well-defined erythema 2
Moderate to severe erythema 3
Severe erythema (beet redness) to slight eschar formation (injuries in depth) 4

Oedema formation:
No oedema 0
Very slight oedema (barely perceptible) 1
Slight oedema (edges of area well-defined by definite raising) 2
Moderate oedema (edges raised approximately 1 millimetre) 3
Severe oedema (raised more than 1 millimetre and extending beyond the area of exposure) 4

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

There were no deaths.

Clinical signs:

other: No signs of systemic toxicity were observed. DERMAL REACTIONS Individual dermal reactions are given in Table 1 and Table 2. Red coloured staining, which prevented evaluation of erythema, was noted at the test sites of all animals one day after patch rem

Gross pathology:

No abnormalities were noted at necropsy.

Table 1 Individual Dermal Reactions (Male)

Animal Number	Observation	Effects Noted After Initiation of Exposure (days)
		1	2	3	4	5	6	7	8	9	10	11	12	13	14
1-0	Erythema Oedema Other	? 0 0	1 0 S	1 0 D	1 0 D	1 0 D	1 0 D	0 0 D	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0
1-1	Erythema Oedema Other	? 0 0	1 0 0	1 0 D	1 0 D	1 0 D	1 0 D	0 0 D	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0
1-2	Erythema Oedema Other	? 0 0	1 0 S	1 0 D	1 0 D	0 0 D	1 0 D	0 0 0	0 0 D	0 0 D	0 0 D	0 0 D	0 0 0	0 0 0	0 0 0
1-3	Erythema Oedema Other	? 0 0	2 0 S	2 0 S,D	2 0 S,D	1 0 S,D	1 0 D	0 0 D	0 0 D	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0
1-4	Erythema Oedema Other	? 0 0	1 0 S	1 0 D	1 0 D	1 0 D	1 0 D	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0	0 0 0

? = Red coloured staining prevented the evaluation or erythema.

S = Pale red coloured staining

D = Moderate desquamation

 

Table 2 Individual Dermal Reactions (Female)

Animal Number

Observation

Effects Noted After Initiation of Exposure (days)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

2-0

Erythema Oedema Other

? 0 0

2 1 S

2 1 S,C

2 1 S,C

2 1 S,C

2 1 C

1 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 0

2-1

Erythema Oedema Other

? 0 0

2 1 S

2 1 S,C

2 1 S,C

2 1 S,C

2 1 C

1 0 C

1 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 0

0 0 0

2-2

Erythema Oedema Other

? 0 0

2 1 S

2 1 C

2 1 C

2 1 C

2 1 C

1 0 C

1 0 C

0 0 C

0 0 C*

0 0 D*

0 0 D

0 0 *

0 0 *

2-3

Erythema Oedema Other

? 0 0

2 1 S

2 1 S,C

2 1 S,C

2 1 S,C

2 1 S,C

1 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 C

0 0 0

2-4

Erythema Oedema Other

? 0 0

2 1 S

2 1 C

2 1 C

2 1 C

2 1 C

1 0 C

0 0 C

0 0 C

0 0 C*

0 0 C*

0 0 C*

0 0 C*

0 0 *

? = Red coloured staining prevented the evaluation or erythema.

S = Pale red coloured staining

D = Moderate desquamation

C = Crust formation

* = Small, superficial, scattered scabs

Interpretation of results:

other: CLP criteria not met

Conclusions:

LD50 >2000 mg/kg bodyweight

Executive summary:

The acute dermal toxicity potential of the test material to Wistar strain rats was assessed in a limit test conducted in accordance with the standardised guidelines OECD 402 and EU Method B.3 under GLP conditions.

A group of 5 male and 5 female animals was given a single dermal dose of the test material to intact skin at a dose level of 2000 mg/kg bodyweight. The test site was covered with a semi-occlusive dressing and left in place for 24 hours. The animals were subsequently observed for 14 days.

There was no mortality and no clinical signs were observed. All animals showed the expected gains in bodyweight throughout the observation period. Signs of dermal irritation noted were very slight to well-defined erythema, very slight oedema, moderate desquamation, crust formation and small, superficial, scattered scabs.

Under the conditions of this study, the acute dermal LD50 was >2000 mg/kg bodyweight and the test material requires no classification in accordance with EU criteria.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The key study was conducted under GLP conditions in accordance with the standardised guidelines OECD 402 and EU Method B.3. It was assigned a reliability score of 1 in accordance with the criteria detailed by Klimisch (1997).

Additional information

Acute Toxicity: Oral

The acute oral toxicity potential of the test material in female Wistar strain rats was assessed in accordance with the standardised guidelines OECD 420 and EU Method B.1bisunder GLP conditions.

Following a sighting test in a single animal at a dose level of 2000 mg/kg, the test material was administered by gavage as a solution in arachis oil BP at the same dose level to an additional four animals. The animals were observed for 14 days.

There was no mortality and no clinical signs were observed. All animals showed the expected gains in bodyweight throughout the observation period.

Under the conditions of this study, the acute oral LD50 was >2000 mg/kg bodyweight and the test material requires no classification in accordance with EU criteria.

 

Acute Toxicity: Inhalation

In accordance with the Column 2 adaptation of Annex VIII of Regulation (EC) 1907/2006 (REACH), it is considered justified to omit the acute toxicity by the inhalation route study (required under point 8.5.2) as testing by this route is inappropriate. Exposure via the inhalation route is not relevant due to the substance being an immobile paste with a low vapour pressure; therefore the acute oral and acute dermal studies are deemed more appropriate to address acute toxicity exposure.

 

Acute Toxicity: Dermal

The acute dermal toxicity potential of the test material to Wistar strain rats was assessed in a limit test conducted in accordance with the standardised guidelines OECD 402 and EU Method B.3 under GLP conditions.

A group of 5 male and 5 female animals was given a single dermal dose of the test material to intact skin at a dose level of 2000 mg/kg bodyweight. The test site was covered with a semi-occlusive dressing and left in place for 24 hours. The animals were subsequently observed for 14 days.

There was no mortality and no clinical signs were observed. All animals showed the expected gains in bodyweight throughout the observation period. Signs of dermal irritation noted were very slight to well-defined erythema, very slight oedema, moderate desquamation, crust formation and small, superficial, scattered scabs.

Under the conditions of this study, the acute dermal LD50 was >2000 mg/kg bodyweight and the test material requires no classification in accordance with EU criteria.

Justification for selection of acute toxicity – oral endpoint
Only one study available.

Justification for selection of acute toxicity – inhalation endpoint
A data waiver has been submitted to address this endpoint.

Justification for selection of acute toxicity – dermal endpoint
Only one study available.

Justification for classification or non-classification

Based on the available data and in accordance with the criteria for classification as defined in Annex I, Regulation 1272/2008, the test material does not require classification for acute toxicity.